Jardiance® (empagliflozin) Phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease Oxford, UK; Ingelheim, Germany and Indianapolis, U.S., Wed, 03/16/2022 - 16:00 Services Print this Press release Tags test
